Randomized trial · people

Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes, this trial found that a once-daily orforglipron pill led to more weight loss than placebo over 72 weeks, with larger losses at higher doses and gut problems as the main side effects that led people to stop.

Kind
Randomized trial
Studied in
People
Number studied
1613
Published
2026
Journal
Lancet

What they tested

The team tested whether orforglipron, a once-daily GLP-1 receptor agonist pill that is not a peptide, helps adults with type 2 diabetes and excess weight lose weight over 72 weeks.

How the study was done

A phase 3, double-blind, randomized, placebo-controlled trial run at 136 sites. It enrolled 1613 adults with type 2 diabetes whose BMI was at least 27 kg/m2 and whose HbA1c (a 3-month average of blood sugar) sat between 7% and 10%. Each person took orforglipron 6 mg, 12 mg or 36 mg, or a placebo (a dummy pill), every day for 72 weeks along with lifestyle changes.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average body weight changed by -5.1% in the 6 mg arm, -7.0% in the 12 mg arm and -9.6% in the 36 mg arm, compared with -2.5% on placebo (all p<0.0001). These results count every randomized person, including those who stopped treatment. HbA1c and all other planned weight and heart-and-metabolism measures improved significantly with orforglipron. The most common side effects were mild-to-moderate stomach and gut problems, mostly while the dose was being stepped up, and 6.1-9.9% of people on orforglipron stopped because of side effects, compared with 4.1% on placebo.

What it doesn’t show

The trial only included adults with type 2 diabetes and an HbA1c of 7-10%, so it does not show results in people without diabetes, and all groups also made lifestyle changes. The study was funded by Eli Lilly and Company.

The paper

Horn et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026.

The compound

More studies on Orforglipron

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo